A5058446760- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Urologic and reproductive health conditions
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Hematological disorders and diagnostics
- Immune Cell Function and Interaction
- Parvovirus B19 Infection Studies
- Renal Diseases and Glomerulopathies
- CNS Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Oral microbiology and periodontitis research
- Renal and Vascular Pathologies
- Renal Transplantation Outcomes and Treatments
- Viral-associated cancers and disorders
- Organ Donation and Transplantation
Presbyterian Hospital
2024-2025
UPMC Presbyterian
2024-2025
Bai Jerbai Wadia Hospital for Children
2024-2025
Baylor College of Medicine
2020-2024
UPMC Health System
2021-2024
University of Pittsburgh
2015-2024
University of Pittsburgh Medical Center
2009-2024
Christian Medical College
2023
Virginia University of Lynchburg
2023
Christian Medical College & Hospital
2023
Indolent T-cell lymphoproliferative disorders of the gastrointestinal tract are rare clonal diseases that more commonly occur in intestines and have a protracted clinical course. Different immunophenotypic subsets been described, but molecular pathogenesis cell origin these lymphocytic proliferations is poorly understood. Hence, we performed targeted next-generation sequencing comprehensive analysis ten indolent tract, which comprised CD4+ (n=4), CD8+ CD4+/CD8+ (n=1) CD4-/CD8- cases. Genetic...
The impact of the immune microenvironment on behavior and therapeutic strategies for hematopoietic lymphoid neoplasms is being increasingly recognized. Many functional studies natural killer (NK) cell cytotoxic responses in myelodysplasia (MDS) acute myeloid leukemia (AML) exist, but with limited data these lymphocyte proportions related T-cell subsets. cells their prognostic implications were therefore investigated 89 AML, 51 MDS, 20 control marrows by flow cytometry. median proportion NK...
The 2016 World Health Organization classification recognized “high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements” (double/triple-hit [DTHL]) lymphoma, not otherwise specified,” which includes non-DTHL a “blastoid” or “intermediate” cytology. Although extensively studied, many questions remain, including cases belong in these categories, factors mitigate their adverse prognosis, when to perform fluorescence situ hybridization studies. Therefore, the clinicopathologic...
β-blocker and calcium channel blocker toxicity generally present with bradycardia hypotension. A 69-year-old woman presented after a suicide attempt overdose. Her blood pressure was 69/35 mm Hg her HR in the 40s. She treated chloride, glucagon, dextrose–insulin infusion three vasopressors, but remained hypotensive. suffered two cardiac arrests required transvenous pacemaker. When all interventions failed, she started on methylene blue for refractory vasodilatory shock which resulted dramatic...
Key Points Blast phenotype is an independent predictor of outcome in NPM1-mutated AML. Patients with a DN blast (lacking CD34 and HLA-DR expression) harbor TET2/IDH mutations show superior outcomes.
PURPOSE Therapy-related acute myeloid leukemias (t-AML) are a heterogenous group of aggressive neoplasms that arise following exposure to cytotoxic chemotherapy and/or ionizing radiation. Many therapy-related (t-MN) associated with distinct chromosomal aberrations TP53 alterations, but little is known about the clinicopathologic and molecular features normal karyotype t-AML (NK-t-AML) whether this t-MN subtype distinctly different from NK de novo AML (NK-dn-AML). METHODS This...
N Context.—The association of circulating donor-specific antibody (DSA) strength with crossmatch results is potential interest to predict allograft outcome. Objectives.—To systematically investigate the aforementioned and attempt define a cutoff value for DSA that can positive result. Design.—We analyzed from 2006 2008 proficiency testing samples American Society Histocompatibility Immunogenetics (n = 50). We further validated our findings in candidates kidney transplant 19)....
Abstract Context.—The association of circulating donor-specific antibody (DSA) strength with crossmatch results is potential interest to predict allograft outcome. Objectives.—To systematically investigate the aforementioned and attempt define a cutoff value for DSA that can positive result. Design.—We analyzed from 2006 2008 proficiency testing samples American Society Histocompatibility Immunogenetics (n = 50). We further validated our findings in candidates kidney transplant 19)....
// Jess F. Peterson 1, 2, 6 , Nidhi Aggarwal 3 Clayton A. Smith 4 Susanne M. Gollin Urvashi Surti Aleksandar Rajkovic 3, 5 Steven H. Swerdlow Svetlana Yatsenko 1 Pittsburgh Cytogenetics Laboratory, Center for Medical Genetics and Genomics, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA 2 Department Human Genetics, University Graduate School Public Health, Pathology, Medicine, Division Hematology, Colorado, Denver, CO, Obstetrics, Gynecology Reproductive Sciences, College Wisconsin,...